scorecardresearch
Add as a preferred source on Google
Friday, April 3, 2026
TopicCovaxin

Topic: Covaxin

Panel formed by Siddaramaiah finds no link between COVID-19 vaccines & Hassan cardiac-related deaths

Expert team, headed by Jayadeva Institute of Cardiovascular Sciences & Research head, has instead said that vaccine has shown to be ‘protective’ against cardiac events.

After filing for Covaxin patent solo, Bharat Biotech to add ICMR as co-inventor

Hyderabad-based vaccine maker says not including ICMR in original patent application for Covaxin was ‘inadvertent error’ & ‘confidential agreement between them was not accessible’.

ICMR seeks retraction of BHU study linking high rate of adverse health events with Covaxin

Study, which said nearly 30 percent of Covaxin recipients suffered from one or other side-effects, is 'misleading', says ICMR head. Journal & authors threatened with legal action.

‘Fake news’ — Bharat Biotech, govt deny report on ‘discrepancies’ in Covaxin trial data

Medical news site STAT had cited internal documents to allege that Bharat Biotech had taken ‘questionable’ steps under political pressure to speed up development of Covaxin.

Covaxin safe for kids, generates higher antibody response in them than adults, says Lancet paper

The results of the phase ⅔ clinical trials of the indigenous Covid vaccine have been peer-reviewed and published in the The Lancet Infectious Diseases journal.

Drug authority clears Covaxin, Corbevax for children aged 5 to 12

DGCI also allowed emergency use of Zycov-D (Zydus Cadila vaccine) for children above 12 years.

As booster uptake lags in pvt sector, officials say health system can’t be in Covid mode forever

Third Covid vaccine dose available only in pvt hospitals. Health officials say routine procedures need to be brought back on track, but govt hospitals could be brought in if needed.

WHO move to suspend Covaxin’s UN supply won’t affect trips to UK, US & over 90 nations, govt says

Bharat Biotech is believed to have assured Government of India that it will ‘quickly’ reply to WHO about ‘deficiencies found in its manufacturing’ during an inspection last month.

Covaxin supplies, trial group size — why there’s a delay in Covid vaccine for younger kids

Monthly Covaxin output between 5.5-6.5 cr. Country needs at least 15 cr doses for full coverage 15-18 age group. Choice of 6 μg dose reduced manufacturing capacity, says Bharat Biotech.

ICMR received Rs 171.74 cr in royalty from sale of Covaxin till 31 Jan, govt tells Rajya Sabha

ICMR and Bharat Biotech developed Covaxin together, and MoS Health Bharati Pawar says in written reply that the research body spent Rs 35 crore on its development.

On Camera

Min Aung Hlaing’s rise in Myanmar matters to India—he is closer to New Delhi than Beijing

Min Aung Hlaing’s move for Myanmar’s presidential post aims for transition to civilian rule, giving the government some legitimacy, headed by a person who no longer dons a uniform.

1973 OPEC oil embargo to US-Israel & Iran war: 6 geopolitical conflicts that shaped India’s energy strategy

Hormuz crisis is only the latest in a line of geopolitical flashpoints that shaped India’s energy strategy over the years, starting from OPEC oil embargo that followed the Yom Kippur war.

India commissions its third nuclear-powered ballistic missile submarine—INS Aridhaman

INS Arihant was first vessel under SSBN project and was quietly commissioned in 2016. The second indigenous SSBN, INS Arighat, was commissioned in August 2024.

Gulf war exposed India’s fragilities. It’s time for navel-gazing, in the national interest

It’s easy to understand why the government can’t speak the hard truth. When this war ends, as all wars do, India’s interests will lie with both the winner and the loser.